JP2014508758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508758A5 JP2014508758A5 JP2013554768A JP2013554768A JP2014508758A5 JP 2014508758 A5 JP2014508758 A5 JP 2014508758A5 JP 2013554768 A JP2013554768 A JP 2013554768A JP 2013554768 A JP2013554768 A JP 2013554768A JP 2014508758 A5 JP2014508758 A5 JP 2014508758A5
- Authority
- JP
- Japan
- Prior art keywords
- cystamine
- analog
- pharmaceutically acceptable
- parkinson
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical class CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 12
- 208000018737 Parkinson disease Diseases 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940099500 cystamine Drugs 0.000 claims 3
- 229960003151 mercaptamine Drugs 0.000 claims 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 2
- -1 Cysteamine cystamine analogue Chemical class 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008717 functional decline Effects 0.000 claims 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001918 neurorescue Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003080 taurine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445577P | 2011-02-23 | 2011-02-23 | |
| US61/445,577 | 2011-02-23 | ||
| CA2,732,440 | 2011-02-23 | ||
| CA2732440A CA2732440C (en) | 2011-02-23 | 2011-02-23 | Cystamine analogues for the treatment of parkinson`s disease |
| PCT/CA2012/050106 WO2012113079A1 (en) | 2011-02-23 | 2012-02-23 | Cystamine analogues for the treatment of parkinson's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508758A JP2014508758A (ja) | 2014-04-10 |
| JP2014508758A5 true JP2014508758A5 (enExample) | 2015-04-09 |
| JP6000985B2 JP6000985B2 (ja) | 2016-10-05 |
Family
ID=46717621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554768A Expired - Fee Related JP6000985B2 (ja) | 2011-02-23 | 2012-02-23 | パーキンソン病を治療するためのシスタミン類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140073694A1 (enExample) |
| EP (1) | EP2678009B1 (enExample) |
| JP (1) | JP6000985B2 (enExample) |
| KR (1) | KR20140115239A (enExample) |
| CN (1) | CN103442704A (enExample) |
| AU (1) | AU2012220314B2 (enExample) |
| BR (1) | BR112013021616A2 (enExample) |
| CA (1) | CA2732440C (enExample) |
| MX (1) | MX350195B (enExample) |
| RU (1) | RU2630583C2 (enExample) |
| WO (1) | WO2012113079A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR096629A1 (es) * | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Métodos para analizar composiciones de cisteamina |
| TW201618760A (zh) * | 2014-11-05 | 2016-06-01 | 雷普特製藥有限公司 | 使用半胱胺組合物治療亨廷頓氏病之方法 |
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| AU2016288230A1 (en) | 2015-07-02 | 2018-01-25 | Horizon Orphan Llc | ADO-resistant cysteamine analogs and uses thereof |
| JP6731488B2 (ja) | 2016-03-30 | 2020-07-29 | オッポ広東移動通信有限公司Ｇｕａｎｇｄｏｎｇ Ｏｐｐｏ Ｍｏｂｉｌｅ Ｔｅｌｅｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｃｏｒｐ．， Ｌｔｄ． | 中継伝送方法及び装置 |
| EP3946298A4 (en) * | 2019-03-26 | 2023-01-25 | The Regents of the University of California | Substituted amino-thiol and amino-disulfide compounds, and uses thereof |
| WO2021022012A1 (en) * | 2019-07-30 | 2021-02-04 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN119909064B (zh) * | 2025-04-07 | 2025-08-15 | 北京大学深圳研究生院 | 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用 |
| CN120437102B (zh) * | 2025-07-09 | 2025-09-16 | 中南大学湘雅医院 | 胱胺在制备治疗脓毒症脑病药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211624A1 (en) * | 2003-02-02 | 2006-09-21 | Goverment of the US, as Represented by | Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies |
| RU2255775C1 (ru) * | 2003-12-25 | 2005-07-10 | Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук | Способ лечения болезни паркинсона |
| MX382184B (es) * | 2006-01-27 | 2025-03-13 | Univ California | Cisteamina recubierta entericamente, cistamina y derivados de ellas. |
| WO2008143876A2 (en) * | 2007-05-14 | 2008-11-27 | The Trustees Of Columia University In The City Of New York | Agents and assays for modulating neurodegeneration |
| JP2011522892A (ja) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
-
2011
- 2011-02-23 CA CA2732440A patent/CA2732440C/en not_active Expired - Fee Related
-
2012
- 2012-02-23 RU RU2013137645A patent/RU2630583C2/ru not_active IP Right Cessation
- 2012-02-23 KR KR1020137024680A patent/KR20140115239A/ko not_active Ceased
- 2012-02-23 WO PCT/CA2012/050106 patent/WO2012113079A1/en not_active Ceased
- 2012-02-23 BR BR112013021616-6A patent/BR112013021616A2/pt not_active IP Right Cessation
- 2012-02-23 MX MX2013009608A patent/MX350195B/es active IP Right Grant
- 2012-02-23 US US14/000,234 patent/US20140073694A1/en not_active Abandoned
- 2012-02-23 EP EP12750124.5A patent/EP2678009B1/en not_active Not-in-force
- 2012-02-23 CN CN2012800099995A patent/CN103442704A/zh active Pending
- 2012-02-23 AU AU2012220314A patent/AU2012220314B2/en not_active Ceased
- 2012-02-23 JP JP2013554768A patent/JP6000985B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508758A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| RU2013137645A (ru) | Аналоги цистамина, применяемые для лечения болезни паркинсона | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2013516442A5 (enExample) | ||
| JP2016523862A5 (enExample) | ||
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2009530385A5 (ja) | うつ病の治療のためのケタミンの投与 | |
| JP2017506624A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2015532296A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| IL272893B2 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2020520963A5 (enExample) | ||
| JP2010514834A5 (enExample) | ||
| Mallhi et al. | Chloroquine and hydroxychloroquine in COVID-19: practice implications for healthcare professionals | |
| JP2015522077A5 (enExample) | ||
| JP2018517759A5 (enExample) | ||
| JP2008534503A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2013536206A5 (enExample) |